박셀바이오, 소액주주와 '소통' 공방…"선별 정보 제공 한계"

This conflict reveals a fundamental tension in biotech: strict disclosure regulations designed to protect market integrity prevent the direct, selective explanations shareholders demand, especially during years-long clinical development. The company's 97% revenue reliance on acquired pet medicine rather than core cancer therapies raises critical questions about whether investor concerns reflect genuine governance failures or unrealistic expectations for long-cycle biotech timelines.